Event

Clinicians face numerous challenges in the management of patients with early stage lung cancer. One of the most difficult aspects is determining the risk of recurrence for early stage patients that are treated surgically. Current treatment options have limited effectiveness and diagnostic tools often provide very limited recurrence risk information. During this interactive, case-based Guru Bar you will hear from experts in the field regarding the need for new biomarkers to better assess the risk of recurrence and their future role in clinical practice.